International Journal of High Risk Behaviors and Addiction

Published by: Kowsar

Stereological Analysis of the Brain in Methamphetamine Abusers Compared to the Controls

Zahra Heidari 1 , 2 , Hamidreza Mahmoudzadeh-Sagheb 1 , 2 , * , Mansour Shakiba 3 and Enam Alhagh Charkhat Gorgich 2
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
3 Department of Clinical Psychology and Psychiatry, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • International Journal of High Risk Behaviors and Addiction: December 2017, 6 (4); e63201
  • Published Online: November 1, 2017
  • Article Type: Research Article
  • Received: August 14, 2016
  • Revised: December 22, 2016
  • Accepted: January 29, 2017
  • DOI: 10.5812/ijhrba.63201

To Cite: Heidari Z, Mahmoudzadeh-Sagheb H, Shakiba M, Alhagh Charkhat Gorgich E. Stereological Analysis of the Brain in Methamphetamine Abusers Compared to the Controls, Int J High Risk Behav Addict. 2017 ;6(4):e63201. doi: 10.5812/ijhrba.63201.

Abstract
Copyright: Copyright © 2017, International Journal of High Risk Behaviors and Addiction. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Granado N, Ares-Santos S, Moratalla R. Methamphetamine and Parkinson's disease. Parkinsons Dis. 2013;2013:308052. doi: 10.1155/2013/308052. [PubMed: 23476887].
  • 2. Yorick R, Skipalska H, Suvorova S, Sukovatova O, Zakharov K, Hodgdon S. HIV Prevention and Rehabilitation Models for Women Who Inject Drugs in Russia and Ukraine. Adv Prev Med. 2012;2012:316871. doi: 10.1155/2012/316871. [PubMed: 23304535].
  • 3. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci. 2006;31(5):301-13. [PubMed: 16951733].
  • 4. Berman S, O'Neill J, Fears S, Bartzokis G, London ED. Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci. 2008;1141:195-220. doi: 10.1196/annals.1441.031. [PubMed: 18991959].
  • 5. Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev. 2009;60(2):379-407. doi: 10.1016/j.brainresrev.2009.03.002. [PubMed: 19328213].
  • 6. Burns L. World drug report 2013 by united nations office on drugs and crime New York: United Nations. Drug Alcohol Rev. 2013;33(2):216.
  • 7. Won L, Bubula N, McCoy H, Heller A. Methamphetamine concentrations in fetal and maternal brain following prenatal exposure. Neurotoxicol Teratol. 2001;23(4):349-54.
  • 8. Hatami H, Mohseni S, Sheikhzadeh F, Nejati F. Comparative study of intraperitoneal injection of heroin and glass on the serum and blood parameters in male rats. J Ilam Univ Med Sci. 2013;21(2):60-7.
  • 9. Summerill A. 2007 National drug strategy household survey: Detailed findings. Australia: Australian Institute of Health and Welfare; 2008.
  • 10. Centers for Disease C.Prevention. Acute public health consequences of methamphetamine laboratories--16 states, January 2000-June 2004. MMWR Morb Mortal Wkly Rep. 2005;54(14):356-9. [PubMed: 15829865].
  • 11. Thomas KV, Bijlsma L, Castiglioni S, Covaci A, Emke E, Grabic R, et al. Comparing illicit drug use in 19 European cities through sewage analysis. Sci Total Environ. 2012;432:432-9. doi: 10.1016/j.scitotenv.2012.06.069. [PubMed: 22836098].
  • 12. Marwick C. NIDA seeking data on effect of fetal exposure to methamphetamine. JAMA. 2000;283(17):2225-6. [PubMed: 10807367].
  • 13. Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW. Methamphetamine self-administration by humans. Psychopharmacology (Berl). 2001;157(1):75-81. [PubMed: 11512046].
  • 14. Barr AM, Markou A. Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci Biobehav Rev. 2005;29(4-5):675-706. doi: 10.1016/j.neubiorev.2005.03.012. [PubMed: 15893821].
  • 15. Barr AM, Markou A, Phillips AG. A 'crash' course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci. 2002;23(10):475-82. [PubMed: 12368072].
  • 16. Makisumi T, Yoshida K, Watanabe T, Tan N, Murakami N, Morimoto A. Sympatho-adrenal involvement in methamphetamine-induced hyperthermia through skeletal muscle hypermetabolism. Eur J Pharmacol. 1998;363(2-3):107-12. [PubMed: 9881575].
  • 17. Rawson R, Huber A, Brethen P, Obert J, Gulati V, Shoptaw S, et al. Methamphetamine and cocaine users: differences in characteristics and treatment retention. J Psychoactive Drugs. 2000;32(2):233-8. doi: 10.1080/02791072.2000.10400234. [PubMed: 10908013].
  • 18. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75(6):406-33. doi: 10.1016/j.pneurobio.2005.04.003. [PubMed: 15955613].
  • 19. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci. 2003;15(3):317-25. doi: 10.1176/jnp.15.3.317. [PubMed: 12928507].
  • 20. Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther. 2001;296(3):762-7. [PubMed: 11181904].
  • 21. Jeng W, Ramkissoon A, Parman T, Wells PG. Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration. FASEB J. 2006;20(6):638-50. doi: 10.1096/fj.05-5271com. [PubMed: 16581972].
  • 22. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci. 2002;22(20):8951-60. [PubMed: 12388602].
  • 23. Mobius C, Kustermann A, Struffert T, Kornhuber J, Muller HH. c-MRI findings after crystal meth abuse. J Addict Med. 2014;8(5):384-5. doi: 10.1097/ADM.0000000000000051. [PubMed: 25026102].
  • 24. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21(23):9414-8. [PubMed: 11717374].
  • 25. Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc. 2004;10(1):1-14. doi: 10.1017/S1355617704101021. [PubMed: 14751002].
  • 26. Chang L, Alicata D, Ernst T, Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction. 2007;102 Suppl 1:16-32. doi: 10.1111/j.1360-0443.2006.01782.x. [PubMed: 17493050].
  • 27. Gunter TD. Control of methamphetamine misuse. BMJ. 2007;334(7605):1176-7. doi: 10.1136/bmj.39225.469630.80. [PubMed: 17556435].
  • 28. Thiriet N, Deng X, Solinas M, Ladenheim B, Curtis W, Goldberg SR, et al. Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J Neurosci. 2005;25(22):5273-9. doi: 10.1523/JNEUROSCI.4893-04.2005. [PubMed: 15930374].
  • 29. Schmued LC, Bowyer JF. Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Res. 1997;759(1):135-40. [PubMed: 9219871].
  • 30. Derauf C, Lester BM, Neyzi N, Kekatpure M, Gracia L, Davis J, et al. Subcortical and cortical structural central nervous system changes and attention processing deficits in preschool-aged children with prenatal methamphetamine and tobacco exposure. Dev Neurosci. 2012;34(4):327-41. doi: 10.1159/000341119. [PubMed: 22907274].
  • 31. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci. 2004;24(26):6028-36. doi: 10.1523/JNEUROSCI.0713-04.2004. [PubMed: 15229250].
  • 32. Apostolova LG, Thompson PM. Brain mapping as a tool to study neurodegeneration. Neurotherapeutics. 2007;4(3):387-400. doi: 10.1016/j.nurt.2007.05.009. [PubMed: 17599704].
  • 33. Kamali Ardakani R, Nahangi H, Yadegari M, Hosseini Sharifabad M. The effects of long-term administration of methamphetamine on the cerebellum of the male mice: A stereological study. Neurosci J Shefaye Khatam. 2014;2(4):37-45.
  • 34. Roberts N, Barbosa S, Blumhardt LD, Kawoski RA, Edwards RH. Stereological estimation of the total volume of MR visible brain lesions in patients with multiple sclerosis. Magn Reson Mater Phys Biol Med. 1994;2(3):375-8.
  • 35. Heidari Z, Mahmoudzadeh-Sagheb H. Quantitative study of volumetric changes of cerebellum in male adult rat following lithium administration. Int J High Risk Behav Addict. 2012;1(2):66-70. doi: 10.5812/ijhrba.4187. [PubMed: 24971235].
  • 36. Heidari Z, Moghtaderi A, Mahmoudzadeh-Sagheb H, Gorgich EAC. Stereological Evaluation of the Brains in Patients with Parkinson’s disease Compared to Controls. Revista Romana de Medicina de Laborator. 2017;25(3):265-74. doi: 10.1515/rrlm-2017-0010.
  • 37. Heidari Z, Sakhavar N, Mahmoudzadeh-Sagheb H, Ezazi-Bojnourdi T. Stereological analysis of human placenta in cases of placenta previa in comparison with normally implanted controls. J Reprod Infertil. 2015;16(2):90-5. [PubMed: 25927025].
  • 38. Heidari Z, Mahmoudzadeh-Sagheb H, Kohan F. A quantitative and qualitative study of rat testis following administration of methadone and buprenorphine. Int J High Risk Behav Addict. 2012;1(1):14-7.
  • 39. Fowler JS, Volkow ND, Kassed CA, Chang L. Imaging the addicted human brain. Sci Pract Perspect. 2007;3(2):4-16. [PubMed: 17514067].
  • 40. Morales AM, Lee B, Hellemann G, O'Neill J, London ED. Gray-matter volume in methamphetamine dependence: cigarette smoking and changes with abstinence from methamphetamine. Drug Alcohol Depend. 2012;125(3):230-8. doi: 10.1016/j.drugalcdep.2012.02.017. [PubMed: 22445480].
  • 41. Mathias R. Methamphetamine brain damage in mice more extensive than previously thought. NIDA Res Monogr. 2000;15(4):1.
  • 42. Aoki Y, Orikabe L, Takayanagi Y, Yahata N, Mozue Y, Sudo Y, et al. Volume reductions in frontopolar and left perisylvian cortices in methamphetamine induced psychosis. Schizophr Res. 2013;147(2-3):355-61. doi: 10.1016/j.schres.2013.04.029. [PubMed: 23688384].
  • 43. Bartzokis G, Beckson M, Lu PH, Edwards N, Rapoport R, Wiseman E, et al. Age-related brain volume reductions in amphetamine and cocaine addicts and normal controls: implications for addiction research. Psychiatry Res. 2000;98(2):93-102. [PubMed: 10762735].
  • 44. Groman SM, Morales AM, Lee B, London ED, Jentsch JD. Methamphetamine-induced increases in putamen gray matter associate with inhibitory control. Psychopharmacology (Berl). 2013;229(3):527-38. doi: 10.1007/s00213-013-3159-9. [PubMed: 23748383].
  • 45. Churchwell JC, Carey PD, Ferrett HL, Stein DJ, Yurgelun-Todd DA. Abnormal striatal circuitry and intensified novelty seeking among adolescents who abuse methamphetamine and cannabis. Dev Neurosci. 2012;34(4):310-7. doi: 10.1159/000337724. [PubMed: 22986770].
  • 46. Snell RS. Clinical neuroanatomy. Lippincott Williams and Wilkins; 2010.
  • 47. Jan RK, Lin JC, Miles SW, Kydd RR, Russell BR. Striatal volume increases in active methamphetamine-dependent individuals and correlation with cognitive performance. Brain Sci. 2012;2(4):553-72. doi: 10.3390/brainsci2040553. [PubMed: 24961260].
  • 48. Ares-Santos S, Granado N, Espadas I, Martinez-Murillo R, Moratalla R. Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology. 2014;39(5):1066-80. doi: 10.1038/npp.2013.307. [PubMed: 24169803].
  • 49. Khoshbouei H, Wang H, Lechleiter JD, Javitch JA, Galli A. Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem. 2003;278(14):12070-7. doi: 10.1074/jbc.M212815200. [PubMed: 12556446].
  • 50. Santiago RM, Barbieiro J, Lima MM, Dombrowski PA, Andreatini R, Vital MA. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):1104-14. doi: 10.1016/j.pnpbp.2010.06.004. [PubMed: 20547199].
  • 51. Toulouse A, Sullivan AM. Progress in Parkinson's disease-where do we stand?. Prog Neurobiol. 2008;85(4):376-92. doi: 10.1016/j.pneurobio.2008.05.003. [PubMed: 18582530].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader